BioNTech SE (WBO:BNTX)
€ 108.9 0.6 (0.55%) Market Cap: 26.09 Bil Enterprise Value: 9.63 Bil PE Ratio: 0 PB Ratio: 1.29 GF Score: 62/100

BioNTech SE at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 04:30PM GMT
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Hello, and welcome to all to the UBS Global Healthcare Conference. My name is Navin Jacob, senior analyst, covering large-cap pharma and smid-cap biotech. Our next presentation and fireside chat is with BioNTech, which had a very successful IPO late 2019. I'm very happy to have with me today Chief Strategic Officer, Ryan Richardson. Ryan, thank you for joining us today.

Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board

Thank you, Navin.

Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

And so -- exactly. So folks on the line, Ryan is going to walk through a few slides here, just to give some backdrop on BioNTech for folks who are not familiar with the name. And then after that, we're going to have a little fireside chat. Go ahead, Ryan.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot